Acyclovir and thymopentin in the treatment of highly recurrent herpes simplex

M. Cusini, G. Tarantini, R. Caputo

Research output: Contribution to journalArticle

Abstract

Long-term acyclovir therapy does not seem to reduce the rate of post-treatment herpetic recurrences. We report the results of long-term acyclovir followed by thymopentin, a synthetic polypeptide derived from the thymic hormone, for the treatment of highly recurrent genital and orofacial herpes simplex. We tried a 3-month regimen with acyclovir followed by 18 weeks of thymopentin in patients suffering from either orofacial or genital herpes. We obtained complete or partial responses with significant reduction in the recurrence rate in 88.9% of patients with orofacial herpes and in 84.6% of patients with genital herpes. We believe that the proposed treatment is of clinical value and is also to be recommended in terms of cost/benefit.

Original languageEnglish
Pages (from-to)13-15
Number of pages3
JournalJournal of Dermatological Treatment
Volume5
Issue number1
DOIs
Publication statusPublished - 1994

Fingerprint

Thymopentin
Herpes Simplex
Acyclovir
Herpes Genitalis
Thymus Hormones
Recurrence
Therapeutics
Cost-Benefit Analysis
Peptides

ASJC Scopus subject areas

  • Dermatology

Cite this

Acyclovir and thymopentin in the treatment of highly recurrent herpes simplex. / Cusini, M.; Tarantini, G.; Caputo, R.

In: Journal of Dermatological Treatment, Vol. 5, No. 1, 1994, p. 13-15.

Research output: Contribution to journalArticle

@article{67ac58445ff0479fab216a858446bd50,
title = "Acyclovir and thymopentin in the treatment of highly recurrent herpes simplex",
abstract = "Long-term acyclovir therapy does not seem to reduce the rate of post-treatment herpetic recurrences. We report the results of long-term acyclovir followed by thymopentin, a synthetic polypeptide derived from the thymic hormone, for the treatment of highly recurrent genital and orofacial herpes simplex. We tried a 3-month regimen with acyclovir followed by 18 weeks of thymopentin in patients suffering from either orofacial or genital herpes. We obtained complete or partial responses with significant reduction in the recurrence rate in 88.9{\%} of patients with orofacial herpes and in 84.6{\%} of patients with genital herpes. We believe that the proposed treatment is of clinical value and is also to be recommended in terms of cost/benefit.",
author = "M. Cusini and G. Tarantini and R. Caputo",
year = "1994",
doi = "10.3109/09546639409081839",
language = "English",
volume = "5",
pages = "13--15",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Acyclovir and thymopentin in the treatment of highly recurrent herpes simplex

AU - Cusini, M.

AU - Tarantini, G.

AU - Caputo, R.

PY - 1994

Y1 - 1994

N2 - Long-term acyclovir therapy does not seem to reduce the rate of post-treatment herpetic recurrences. We report the results of long-term acyclovir followed by thymopentin, a synthetic polypeptide derived from the thymic hormone, for the treatment of highly recurrent genital and orofacial herpes simplex. We tried a 3-month regimen with acyclovir followed by 18 weeks of thymopentin in patients suffering from either orofacial or genital herpes. We obtained complete or partial responses with significant reduction in the recurrence rate in 88.9% of patients with orofacial herpes and in 84.6% of patients with genital herpes. We believe that the proposed treatment is of clinical value and is also to be recommended in terms of cost/benefit.

AB - Long-term acyclovir therapy does not seem to reduce the rate of post-treatment herpetic recurrences. We report the results of long-term acyclovir followed by thymopentin, a synthetic polypeptide derived from the thymic hormone, for the treatment of highly recurrent genital and orofacial herpes simplex. We tried a 3-month regimen with acyclovir followed by 18 weeks of thymopentin in patients suffering from either orofacial or genital herpes. We obtained complete or partial responses with significant reduction in the recurrence rate in 88.9% of patients with orofacial herpes and in 84.6% of patients with genital herpes. We believe that the proposed treatment is of clinical value and is also to be recommended in terms of cost/benefit.

UR - http://www.scopus.com/inward/record.url?scp=0028204281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028204281&partnerID=8YFLogxK

U2 - 10.3109/09546639409081839

DO - 10.3109/09546639409081839

M3 - Article

AN - SCOPUS:0028204281

VL - 5

SP - 13

EP - 15

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 1

ER -